Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7936
Peer-review started: November 18, 2021
First decision: February 7, 2022
Revised: February 21, 2022
Accepted: June 26, 2022
Article in press: June 26, 2022
Published online: August 6, 2022
Processing time: 245 Days and 23.2 Hours
Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN), which consists of neuroendocrine and non-neuroendocrine components, is quite rare. Until now, most data on gastric MiNEN come from clinical cases, without large-scale retrospective studies or controlled clinical trials. Consequently, no consensus regarding the origin, molecular characteristics, or appropriate treatment of MiNEN has been reached so far. We conducted chemotherapy of irinotecan plus cisplatin (IP regimen) and surgery in two patients with gastric MiNEN, which had never been used in treating this kind of tumor, leading to their long-term survival for more than 3 and 7 years, respectively.
We present two patients (one male and one female) with gastric MiNEN, with the primary manifestation of recurrent upper abdominal pain. After they were referred to our hospital, a diagnosis of gastric MiNEN was defined with the help of CT scan, and histopathological and immunohistochemical examinations on the samples of gastrointestinal endoscopy or radical surgery. The male patient (case 1) were found to have metastases in the reginal lymph nodes and the left liver. He received four cycles of IP regimens first, then the gastrectomy and partial left liver resection, followed by additional two cycles of IP chemotherapy. The female patient (case 2) underwent a laparoscopic gastrectomy, and received six cycles of IP regimen. She was found to have metastatic lesions in the right lung 2 years after that, and underwent video-assisted thoracoscopic surgery (VATS) of the lower lobe of the right lung. The two patients have now survived for more than 3 years and 7 years, respectively, without any evidence of recurrence or metastases.
IP regimen, combined with curative-intent surgery if feasible, could be considered as the priority in the choice of front-line chemotherapy for gastric MiNEN.
Core Tip: Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) is a rare, highly aggressive tumor with a poor prognosis (median overall survival less than 12 mo), and no consensus regarding the appropriate treatment has been reached so far. We conducted chemotherapy of irinotecan plus cisplatin regimen and surgery in two patients with gastric MiNEN, which had not been used to treat this kind of tumor before, leading to their long-term survival for more than 3 and 7 years, respectively. Our reports may provide a reference for other clinicians.